Glioblastoma…if failure or intolerance to the preferred or other recommended regimens…BRAF V600E activation mutation…BRAF/MEK inhibitors…Dabrafenib/trametinib

TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.

The dabrafenib/trametinib (D/T) subgroup had the longest median PFS (5.23 mo), a disease control rate (DCR) of 77%, an objective response rate of 22%, and a median duration of response of 22.5 mo...Our results confirm the activity of D/T in BRAFV600E mutant rGBM.

...phase 2 basket study (NCT02034110) of dabrafenib + trametinib in pts with BRAF V600E mutation-positive...The majority had glioblastoma (69%)...Median (range) follow-up was 12.7 (1.1-56.1) months (mo); ORR was 33% (3 CR, 12 PR); median DOR was 36.9 mo (95% CI, 7.4-44.2). Median PFS and OS were 3.8 mo (95% CI, 1.8-9.2) and 17.6 mo (95% CI, 9.5-45.2), respectively.

We describe four patients with BRAF V600 E mutated gliomas, including a 21-year-old woman with a ganglioglioma WHO grade I, a 19-year-old man with a pleomorphic xanthoastrocytoma WHO grade III, and 21-year-old and 33-year-old women with epithelioid GBM WHO grade IV, who achieved durable progression-free survival with combination BRAF/MEKi.

Here we present the case of a young female with BRAF V600E-mutant eGBM who had a prolonged response to targeted therapy with the BRAF and MEK1/2 inhibitors dabrafenib and trametinib.